



BLISS GVS PHARMA LIMITED

CIN: L24230MH1984PLC034771

Regd. Office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai - 400 072.

Consolidated Q2 FY 16
operating revenue at ₹ 270.95 cr

Consolidated Q2 FY 16
PBT at ₹ 74.05 cr

Standalone Q2 FY 16
Operating revenue at ₹ 173.91 cr

Standalone Q2 FY 16
PBT at ₹ 59.40 cr

The aforesaid highlights are a compilation of consolidated financials and other information all of which have not been audited.

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.09.2015

PART - I

(Rs. in Lacs)

SR. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			HALF YEAR ENDED		YEAR ENDED
		30.09.2015 (UNAUDITED)	30.06.2015 (UNAUDITED)	30.09.2014 (UNAUDITED)	30.09.2015 (UNAUDITED)	30.09.2014 (UNAUDITED)	31.03.2015 (AUDITED)
1	Income From Operations						
	(a) Net Sales (Net of Excise Duty)	9268.54	7982.83	8755.69	17251.37	15736.57	30945.89
	(b) Other Operating Income	97.97	42.06	173.72	140.03	171.27	356.28
	Total Income From Operations (Net)	9366.51	8024.88	8929.41	17391.40	15907.84	31302.17
2	Expenses						
	a) Consumption of Raw Materials	3715.49	3483.87	4,219.51	7,199.36	6,796.19	13784.13
	b) Purchase of Traded Goods	0.00	36.37	90.32	36.37	90.32	90.32
	c) Changes in inventories of finished goods, work in progress, Stock in Trade	-191.83	15.90	17.62	-175.93	285.73	248.27
	d) Employee Benefit Expenses	564.07	482.58	409.13	1046.65	807.97	1736.08
	e) Depreciation / Amortisation	157.67	135.22	118.48	292.88	231.41	507.83
	f) Other Expenditure	2233.59	1577.41	1298.64	3811.00	2996.94	6823.95
	Total Expenses	6478.99	5731.34	6153.69	12210.33	11208.55	23190.58
3	Profit From Operations Before Other Income & Finance Cost & Exceptional Items (1-2)	2887.52	2293.55	2775.72	5181.07	4699.30	8111.59
4	Other Income	836.24	630.78	713.38	1467.02	1071.81	2135.03
5	Profit From Ordinary Activities Before Finance Cost (3+4)	3723.76	2924.33	3489.10	6648.09	5771.11	10246.63
6	Finance Cost	416.24	291.18	251.17	707.42	475.15	1121.18
7	Profit From Ordinary Activities After Finance Cost But Before Exceptional Items (5-6)	3307.52	2633.15	3237.92	5940.67	5295.95	9125.45
8	Exceptional Items	-	-	-	-	-	-
9	Profit From Ordinary Activities Before Tax (7-8)	3307.52	2633.15	3237.92	5940.67	5295.95	9125.45
10	Tax Expense (including Deferred Tax)	891.28	1092.90	1081.20	1984.18	1739.77	3123.90
11	Net Profit After Tax For The Period (9-10)	2416.24	1540.25	2156.72	3956.49	3556.18	6001.55
12	Paid-Up Equity Capital	1031.47	1031.47	1031.47	1031.47	1031.47	1031.47
13	Reserves Excluding Revaluation Reserve (as Per Balance Sheet)	-	-	-	-	-	35787.14
14	Basic And Diluted Eps (Not Annualised)	2.34	1.49	2.09	3.84	3.45	5.82

SR. No.	PARTICULARS	Quarter Ended 30th September 2015	
B	INVESTOR COMPLAINTS		
	Pending at the beginning of the quarter	-	-
	Received during the quarter	5	5
	Disposed off during the quarter	5	5
	REMAINING UNSOLVED AT THE END OF THE QUARTER	-	-

STATEMENT OF ASSETS AND LIABILITIES AS AT 30TH SEPTEMBER, 2015. (Rs. in Lacs)

SR. No.	PARTICULARS	STANDALONE	
		Sep - 15	Mar - 15
I.	EQUITY AND LIABILITIES		
1	SHAREHOLDERS' FUNDS:		
	(i) Share Capital	1,031.47	1,031.47
	(ii) Reserves and Surplus	40,175.08	35,787.14
	(iii) Money received against share warrants	-	-
	Sub-total - Shareholders' funds	41,206.55	36,818.61
2	Non-Current liabilities		
	(i) Long term Borrowings	1,327.75	3,020.95
	(ii) Deferred tax liabilities (Net)	799.07	715.30
	(iii) Long term provisions	154.85	139.85
	Sub-total - Non-current liabilities	2,281.67	3,876.10
3	Current liabilities		
	(i) Short term Borrowings	2,765.88	2,837.62
	(ii) Trade payables	6,031.68	5,046.72
	(iii) Other current liabilities	5,028.35	3,913.46
	(iv) Short term provisions	3,160.68	3,007.62
	Sub-total-current liabilities	16,986.59	14,805.42
	Total.....	60,474.81	55,500.13
II.	ASSETS		
1	Non-current assets		
	(a) Fixed Assets	8,016.56	8,150.39
	(b) Non-current Investments	2,059.37	1,922.63
	(c) Long term loans and advances	11,285.53	10,135.08
	(d) Other non current assets	-	43.26
	Sub-total - Non-current assets	21,361.46	20,251.36
2	Current assets		
	(a) Inventories	2,559.70	2,251.83
	(b) Trade receivables	25,249.72	21,061.21
	(c) Cash and Bank balances	5,722.02	4,736.77
	(d) Short term loans and advances	4,393.76	6,133.62
	(e) Other current assets	1,188.15	1,065.34
	Sub-total - Current assets	39,113.35	35,248.77
	Total.....	60,474.81	55,500.13

Notes:

- The company operates primarily in the Pharmaceutical Business and hence has only one reportable segment.
- The above results were reviewed by the audit committee & were there after approved by the board at its meeting held on November 09, 2015
- The statutory auditors have carried out a limited review of the results for the quarter ended September 30, 2015
- Figures for the previous periods have been regrouped/rearranged wherever necessary.

FOR BLISS GVS PHARMA LIMITED
SD/-

Place : Mumbai
Date : 09th November, 2015

S. N. KAMATH
MANAGING DIRECTOR

PART - II

(Rs. in Lacs)

SR. No.	PARTICULARS	STANDALONE					
		QUARTER ENDED			SIX MONTHS ENDED		YEAR ENDED
		30.09.2015 (UNAUDITED)	30.06.2015 (UNAUDITED)	30.09.2014 (UNAUDITED)	30.09.2015 (UNAUDITED)	30.09.2014 (UNAUDITED)	31.03.2015 (AUDITED)
A	Particulars of Shareholding						
1	Aggregate of Non-promoter Shareholding						
	- No. of Shares (Face Value Rs.1/- Each)	39899426	36156842	36156842	39899426	36156842	36156842
	- Percentage of Shareholding (%)	38.68	35.05	35.05	38.68	35.05	35.05
2	Promoter and Promoter Group Shareholding						
	A) Pledge/ Encumbered						
	- No. of Shares (Face Value Re.1/- Each)	-	-	-	-	-	-
	- Percentage of Shares (As % of the total Share Holding of Promoter & Promoter Group)	-	-	-	-	-	-
	- Percentage of Shares (As % of the total Share Capital of The Company)	-	-	-	-	-	-
	B) Non - Encumbered						
	- No. of Shares (Face Value Re.1/- Each)	63247246	66989830	66989830	63247246	66989830	66989830
	- Percentage of Shares (As % of the total Share Holding of Promoter & Promoter Group)	100.00	100.00	100.00	100.00	100.00	100.00
	- Percentage of Shares (As % of the total Share Capital of The Company)	61.32	64.95	64.95	61.32	64.95	64.95

Limited Review Report

The Board of Directors
Bliss GVS Pharma Limited
Mumbai

We have reviewed the accompanying Statement of unaudited financial results of Bliss GVS Pharma Limited for the quarter ended September 30, 2015 ("the Statement") except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding', which have been traced from disclosures, made by the management and have not been reviewed by us. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.


We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with the Accounting Standards specified under Section 133 of the Companies Act, 2013, read with rule 7 of the Companies (Accounts) Rules, 2014 (as amended) and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

We draw attention to our reliance on management representation, in respect of the realisability of the Company's investment in and loan given to two of its subsidiaries (net of the amount realisable in on disposal of a step down subsidiary) aggregating Rs. 7,696 lakhs.

Our conclusion is not modified in respect of this matter.

For B. K. Khare & Co.
Chartered Accountants
Firm Registration No. 105102W



Himanshu Chapsey
Partner
Membership No. 105731
Mumbai, November 9, 2015

**Pune**

T + 91 020 60601005/6/7/8/9
+ 91 020 25666932/32926341

E bkkpune@bkkhareco.com
Hotel Swaroop, 4th Floor,
Lane No.10, Prabhat Road,
Erandwane, Pune - 411 004, India

Bengaluru

T + 91 80 41105357
E bkkbengaluru@bkkhareco.com

101, Money Chambers,
1st Floor, # 6 K. H. Road,
Shanthinagar,
Bengaluru - 560027, India

New Delhi

T + 91 011 4182 8360
E bkkdelhi@bkkhareco.com

107, Siddharth Chambers,
Near IIT Gate,
Kalu Sarai, Hauz Khas,
New Delhi - 110 016, India.